YMAB stock holds steady as Y-Mabs Therapeutics builds on recent revenue growth

Y-Mabs Therapeutics stock (ISIN US9842411095) is trading in a relatively steady range as of early September 2026, while the biotech company continues to show modest revenue growth and maintains a solid cash position to fund its oncology pipeline, according to recent financial data as of Q2 fiscal 2025.

Revenue trends and recent filings

According to an overview of Y-Mabs Therapeutics filings compiled by a financial data portal based on SEC 10-K and 10-Q reports, the company generated revenue of 87.7 million USD in fiscal year 2024, representing an increase of 3.4 percent compared with the prior fiscal year 2023, with revenue for 2023 therefore standing at about 84.8 million USD.

The same dataset shows that over the trailing twelve months from Q3 fiscal 2024 through Q2 fiscal 2025, Y-Mabs Therapeutics achieved 85.4 million USD in revenue, illustrating that the company has largely maintained its revenue level while shifting its mix over the most recent quarters.

These figures are rooted in SEC filings, with the latest reported period listed as Q2 fiscal 2025 ended June 30, 2025, which falls well within the current freshness window relative to September 5, 2026 and counts as the most recently reported interim period available for investors following YMAB stock.

Cash position and funding capacity

In addition to revenue trends, Y-Mabs Therapeutics cash and equivalents provide important context for YMAB stock. A quarterly breakdown based on SEC filings shows that cash and equivalents stood at 62.3 million USD in Q2 fiscal 2025, which corresponds to a decrease of 19.9 percent compared with the same quarter a year earlier when cash and equivalents were around 77.8 million USD.

The same cash series indicates that at multiple earlier points, such as Q4 fiscal 2022, cash and equivalents were higher at 105.8 million USD, underscoring that while the company has drawn down its cash balance over several years, it still retains a meaningful buffer to support operations, clinical trials and potential regulatory filings in the near term.

For investors following YMAB stock, the combination of modest revenue growth and a still significant cash position is central to assessing dilution risk and the company’s ability to finance its oncology-focused strategy without immediate large-scale external funding.

Product and pipeline context

Y-Mabs Therapeutics focuses on antibody-based treatments for oncology indications, with its product and pipeline strategy aimed at addressing pediatric and adult cancers where current therapies can be improved. The company’s revenue base in fiscal year 2024 and into Q2 fiscal 2025 reflects ongoing commercialization and licensing activity linked to this portfolio rather than broad, diversified pharmaceutical operations.

Historical context from the revenue figures shows that the 3.4 percent rise in revenue from fiscal year 2023 to fiscal year 2024 is modest in absolute terms but nevertheless marks progress in scaling the business, which is important for a specialized biotech whose valuation and YMAB stock performance ultimately depend on converting scientific assets into cash-generating products.

Stock and market perspective

While detailed intraday price data for YMAB stock on September 5, 2026 are not discussed here, the most recent filings up to Q2 fiscal 2025 ended June 30, 2025, along with the revenue and cash figures cited above, frame the fundamental backdrop for the share price as of early September 2026.

Investors analyzing YMAB stock can therefore anchor their view in three key figures: fiscal year 2024 revenue of 87.7 million USD, up 3.4 percent year on year; trailing twelve-month revenue of 85.4 million USD through Q2 fiscal 2025; and cash and equivalents of 62.3 million USD in Q2 fiscal 2025, down from 77.8 million USD in the comparable quarter a year earlier. Together, these numbers highlight both the progress and the funding challenges that define Y-Mabs Therapeutics current investment case.

For retail investors, the quantified comparison between the 3.4 percent revenue increase and the 19.9 percent decline in cash year on year in Q2 fiscal 2025 provides a concise gauge of how growth and liquidity are evolving side by side, which is crucial when considering exposure to YMAB stock in the volatile biotech segment.